First Tracks Biotherapeutics (NASDAQ:TRAX – Free Report) – Equities research analysts at HC Wainwright decreased their Q2 2026 EPS estimates for First Tracks Biotherapeutics in a research note issued on Wednesday, July 8th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($0.90) per share for the quarter, down from their previous forecast of ($0.86). HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock.
TRAX has been the topic of a number of other research reports. Wells Fargo & Company assumed coverage on shares of First Tracks Biotherapeutics in a research note on Monday, June 8th. They set an “overweight” rating and a $30.00 target price on the stock. Barclays started coverage on First Tracks Biotherapeutics in a report on Wednesday, April 22nd. They set an “overweight” rating and a $40.00 price target on the stock. Wedbush began coverage on First Tracks Biotherapeutics in a research report on Friday, April 24th. They issued an “outperform” rating and a $30.00 price objective on the stock. Piper Sandler assumed coverage on First Tracks Biotherapeutics in a research note on Monday, May 4th. They issued an “overweight” rating and a $54.00 price objective for the company. Finally, Zacks Research upgraded First Tracks Biotherapeutics to a “hold” rating in a research report on Monday, April 27th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $38.25.
First Tracks Biotherapeutics Trading Up 56.0%
TRAX opened at $32.40 on Friday. The company has a market capitalization of $1.13 billion and a price-to-earnings ratio of -17.61. First Tracks Biotherapeutics has a 1-year low of $14.72 and a 1-year high of $33.70. The stock has a 50 day moving average price of $18.20.
Further Reading
- Five stocks we like better than First Tracks Biotherapeutics
- PepsiCo’s Dividend Could Turn Patience Into Real Profit
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
Receive News & Ratings for First Tracks Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Tracks Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
